An investigation into the potential use of nanoparticles as adjuvants for the production of polyclonal antibodies to low molecular weight compounds

Suja E. George*, Christopher T. Elliott, Declan P. McLaughlin, Philippe Delahaut, Takami Akagi, Mitsuru Akashi, Terence L. Fodey

*Corresponding author for this work

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Two nanoparticle based adjuvants were assessed for their ability to produce polyclonal antibodies in rabbits to low molecular weight target analytes, i.e. veterinary drugs banned from use in food producing animals. The nanoparticles, Montanide IMS 251 and amphiphilic poly (γ-glutamic acid) were compared against a mineral oil adjuvant, Montanide ISA 50, which had previously been shown to be successful in producing antibodies to haptens whilst being safe to use with respect to the welfare of the host animals. The adjuvants were assessed for their tendency to cause adverse effects to the host animals and by the quality of the antibodies generated in terms of assay sensitivity. None of the three adjuvants employed in the trial generated any measurable adverse effects in the host animals. While the mineral oil adjuvant produced higher titres of antibodies the nanoparticle adjuvants were found to produce antibodies of statistically comparable sensitivity. Based on IC50 values, six antisera displayed potential to detect the required level of the target compounds; five of these were produced by rabbits immunised with the two different nanoparticle adjuvants. As antibody sensitivity is the main performance criteria of an analytical immunoassay, it can be concluded that the nanoparticle adjuvants under evaluation are fit for the purpose described in this study.

Original languageEnglish
Pages (from-to)46-53
Number of pages8
JournalVeterinary Immunology and Immunopathology
Volume149
Issue number1-2
DOIs
Publication statusPublished - 15 Sep 2012

Fingerprint

nanoparticles
polyclonal antibodies
Nanoparticles
adjuvants
Antibody Formation
Molecular Weight
molecular weight
Antibodies
Mineral Oil
antibodies
mineral oil
Veterinary Drugs
Rabbits
Animal Welfare
animals
Haptens
polyglutamic acid
rabbits
adverse effects
Immunoassay

Keywords

  • Adjuvant
  • Antibody
  • ELISA
  • Immunoassay
  • Nanoparticles

Cite this

George, Suja E. ; Elliott, Christopher T. ; McLaughlin, Declan P. ; Delahaut, Philippe ; Akagi, Takami ; Akashi, Mitsuru ; Fodey, Terence L. / An investigation into the potential use of nanoparticles as adjuvants for the production of polyclonal antibodies to low molecular weight compounds. In: Veterinary Immunology and Immunopathology. 2012 ; Vol. 149, No. 1-2. pp. 46-53.
@article{eff4e868b80944ddb34c814d6d0eac15,
title = "An investigation into the potential use of nanoparticles as adjuvants for the production of polyclonal antibodies to low molecular weight compounds",
abstract = "Two nanoparticle based adjuvants were assessed for their ability to produce polyclonal antibodies in rabbits to low molecular weight target analytes, i.e. veterinary drugs banned from use in food producing animals. The nanoparticles, Montanide IMS 251 and amphiphilic poly (γ-glutamic acid) were compared against a mineral oil adjuvant, Montanide ISA 50, which had previously been shown to be successful in producing antibodies to haptens whilst being safe to use with respect to the welfare of the host animals. The adjuvants were assessed for their tendency to cause adverse effects to the host animals and by the quality of the antibodies generated in terms of assay sensitivity. None of the three adjuvants employed in the trial generated any measurable adverse effects in the host animals. While the mineral oil adjuvant produced higher titres of antibodies the nanoparticle adjuvants were found to produce antibodies of statistically comparable sensitivity. Based on IC50 values, six antisera displayed potential to detect the required level of the target compounds; five of these were produced by rabbits immunised with the two different nanoparticle adjuvants. As antibody sensitivity is the main performance criteria of an analytical immunoassay, it can be concluded that the nanoparticle adjuvants under evaluation are fit for the purpose described in this study.",
keywords = "Adjuvant, Antibody, ELISA, Immunoassay, Nanoparticles",
author = "George, {Suja E.} and Elliott, {Christopher T.} and McLaughlin, {Declan P.} and Philippe Delahaut and Takami Akagi and Mitsuru Akashi and Fodey, {Terence L.}",
year = "2012",
month = "9",
day = "15",
doi = "10.1016/j.vetimm.2012.06.002",
language = "English",
volume = "149",
pages = "46--53",
journal = "Veterinary Immunology and Immunopathology",
issn = "0165-2427",
publisher = "Elsevier",
number = "1-2",

}

An investigation into the potential use of nanoparticles as adjuvants for the production of polyclonal antibodies to low molecular weight compounds. / George, Suja E.; Elliott, Christopher T.; McLaughlin, Declan P.; Delahaut, Philippe; Akagi, Takami; Akashi, Mitsuru; Fodey, Terence L.

In: Veterinary Immunology and Immunopathology, Vol. 149, No. 1-2, 15.09.2012, p. 46-53.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An investigation into the potential use of nanoparticles as adjuvants for the production of polyclonal antibodies to low molecular weight compounds

AU - George, Suja E.

AU - Elliott, Christopher T.

AU - McLaughlin, Declan P.

AU - Delahaut, Philippe

AU - Akagi, Takami

AU - Akashi, Mitsuru

AU - Fodey, Terence L.

PY - 2012/9/15

Y1 - 2012/9/15

N2 - Two nanoparticle based adjuvants were assessed for their ability to produce polyclonal antibodies in rabbits to low molecular weight target analytes, i.e. veterinary drugs banned from use in food producing animals. The nanoparticles, Montanide IMS 251 and amphiphilic poly (γ-glutamic acid) were compared against a mineral oil adjuvant, Montanide ISA 50, which had previously been shown to be successful in producing antibodies to haptens whilst being safe to use with respect to the welfare of the host animals. The adjuvants were assessed for their tendency to cause adverse effects to the host animals and by the quality of the antibodies generated in terms of assay sensitivity. None of the three adjuvants employed in the trial generated any measurable adverse effects in the host animals. While the mineral oil adjuvant produced higher titres of antibodies the nanoparticle adjuvants were found to produce antibodies of statistically comparable sensitivity. Based on IC50 values, six antisera displayed potential to detect the required level of the target compounds; five of these were produced by rabbits immunised with the two different nanoparticle adjuvants. As antibody sensitivity is the main performance criteria of an analytical immunoassay, it can be concluded that the nanoparticle adjuvants under evaluation are fit for the purpose described in this study.

AB - Two nanoparticle based adjuvants were assessed for their ability to produce polyclonal antibodies in rabbits to low molecular weight target analytes, i.e. veterinary drugs banned from use in food producing animals. The nanoparticles, Montanide IMS 251 and amphiphilic poly (γ-glutamic acid) were compared against a mineral oil adjuvant, Montanide ISA 50, which had previously been shown to be successful in producing antibodies to haptens whilst being safe to use with respect to the welfare of the host animals. The adjuvants were assessed for their tendency to cause adverse effects to the host animals and by the quality of the antibodies generated in terms of assay sensitivity. None of the three adjuvants employed in the trial generated any measurable adverse effects in the host animals. While the mineral oil adjuvant produced higher titres of antibodies the nanoparticle adjuvants were found to produce antibodies of statistically comparable sensitivity. Based on IC50 values, six antisera displayed potential to detect the required level of the target compounds; five of these were produced by rabbits immunised with the two different nanoparticle adjuvants. As antibody sensitivity is the main performance criteria of an analytical immunoassay, it can be concluded that the nanoparticle adjuvants under evaluation are fit for the purpose described in this study.

KW - Adjuvant

KW - Antibody

KW - ELISA

KW - Immunoassay

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84865537843&partnerID=8YFLogxK

U2 - 10.1016/j.vetimm.2012.06.002

DO - 10.1016/j.vetimm.2012.06.002

M3 - Article

C2 - 22749700

AN - SCOPUS:84865537843

VL - 149

SP - 46

EP - 53

JO - Veterinary Immunology and Immunopathology

JF - Veterinary Immunology and Immunopathology

SN - 0165-2427

IS - 1-2

ER -